Topical tofacitinib for the management of lymphocytic-variant hypereosinophilic syndrome with cutaneous involvement

Dermatol Ther. 2022 Jul;35(7):e15518. doi: 10.1111/dth.15518. Epub 2022 May 17.

Authors

Jordan T Said^{1

2}, Scott A Elman¹, Marianne Tawa³, David C Fisher^{2

4}, Joseph F Merola^{1

2

5}, Thomas S Kupper^{1

2

3}

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Harvard Medical School, Boston, Massachusetts, USA.
³ Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
⁴ Medical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
⁵ Division of Rheumatology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

PMID: 35426208
DOI: 10.1111/dth.15518

No abstract available

Publication types

Letter

MeSH terms

Humans
Hypereosinophilic Syndrome* / diagnosis
Hypereosinophilic Syndrome* / drug therapy
Piperidines
Pyrimidines

Substances

Piperidines
Pyrimidines
tofacitinib